Keryx Licenses Japanese Rights For Zerenex To Japan Tobacco In $100 Million Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Keryx CEO says the novel phosphate binder has advantages over treatments such as Genzyme’s Renagel.
You may also be interested in...
Genzyme Gets Mixed Results On Renvela Powder Formulation
An NDA for the tablet form of the follow-on chronic kidney disease therapy is pending at FDA.
Amgen Gains Phase II Phosphate Binder With Acquisition of Ilypsa
Ilypsa’s lead candidate, ILY1001, for treatment of hyperphosphatemia in chronic kidney disease, complements Amgen’s anemia agents.
Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.